Boston Scientific Corp. Sees Unusually Large Options Volume (BSX)
Shares of Boston Scientific Corp. (NYSE:BSX) was the target of some unusual options trading activity on Tuesday. Stock investors bought 35,723 call options on the stock, AnalystRatingsNetwork reports. This represents an increase of approximately 454% compared to the typical volume of 6,451 call options.
BSX has been the subject of a number of recent research reports. Analysts at Piper Jaffray upgraded shares of Boston Scientific Corp. from a “neutral” rating to an “overweight” rating in a research note to investors on Tuesday. They now have a $18.00 price target on the stock, up previously from $12.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific Corp. in a research note to investors on Tuesday, January 14th. They now have a $14.00 price target on the stock. Finally, analysts at Barclays raised their price target on shares of Boston Scientific Corp. from $13.00 to $14.00 in a research note to investors on Thursday, January 9th. They now have an “overweight” rating on the stock. Twelve research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $11.59.
Boston Scientific Corp. (NYSE:BSX) traded up 3.48% on Tuesday, hitting $13.98. 20,088,072 shares of the company’s stock traded hands. Boston Scientific Corp. has a 1-year low of $6.65 and a 1-year high of $13.68. The stock has a 50-day moving average of $12.08 and a 200-day moving average of $11.45. The company’s market cap is $18.666 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.17 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.09 by $0.08. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.73 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Boston Scientific Corp. will post $0.45 EPS for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.